Compounds > u 77779
Page last updated: 2024-08-24

u 77779 and Neoplasms

u 77779 has been researched along with Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berg, K; Hammond, LA; Patnaik, A; Rizzo, J; Rowinsky, EK; Schwartz, GH; Von Hoff, DD1
Adjei, AA; Ames, MM; Atherton, P; Bagniewski, PG; Erlichman, C; Goldberg, RM; Pitot, HC; Rayson, D; Reid, JM; Rubin, J; Sloan, JA1

Trials

2 trial(s) available for u 77779 and Neoplasms

ArticleYear
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Duocarmycins; Female; Humans; Indoles; Intercalating Agents; Male; Middle Aged; Neoplasms; Urea

2003
A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Availability; Duocarmycins; Female; Humans; Indoles; Injections, Intravenous; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutrophils; Urea

2002